Dr. Kotini Foundation is non-profit organization registered as trust, founded at Rajampalem, West Godavari district of Andhra Pradesh, India. It is founded by Dr. Suresh Babu Kotini.
Legal status and registrations:
Major objects:
Dear Sir/madam,
The Foundation’s main focus is to provide access to quality education for all and promotion of Research and Development in the field of Medical Science. To achieve this, the Foundation provides scholarships to the talented young students mainly from economically backward sections, and supports them for having access to qualitative higher education. We believe that lack of education is one of the biggest barriers that prevents’ people from leading healthy, qualitative and productive lives. Proper education plays a crucial role making the society a better place which ultimately builds the culture of peace.
The Foundation strongly believes that a better and peaceful society where all the people can lead healthy, qualitative and productive lives can be achieved only by providing quality education to the needy, deserving and economically disadvantaged students who have God gifted talents. Due to the lack of financial support, those talents and intelligences should never go waste but should be properly harnessed not only for the individuals’ growth but also for the creation of a better society. The Foundation’s purpose of providing scholarships is not only to make deserving people educated, but also to make them ‘knowledge persons’ who would be able to make the nation move forward and who would also strive to make the nation prosperous.
Another major focus of the Foundation’s mission is to work on Healthcare, Science and Research thereby bringing up Innovative Projects in the area of drug (medicines) discovery in the medical field and Inventing and Developing novel antibiotics for treating life-threatening infectious diseases. The scientific team of the Foundation is particularly interested and focused on developing medicines (e.g. antibiotics) against mycobacterium tuberculosis, a causative agent of tuberculosis (TB) disease and ESKAPE pathogens (those which cause various life-threatening infections) etc.
The Foundation believes that all the great people who have achieved great things in their lives could do so only because they could get access to quality higher education and immense exposure and access to state of art research facilities in their fields. For the Foundation and to me personally too, education is an admirable thing and if there is anything which could contribute to the development of our society, it is to provide quality education to the economically disadvantaged meritorious students and to direct all possible efforts to the field of Healthcare and Research for the Development of new/novel class of medicines (antibiotics) against life-threatening infectious diseases (e.g. Tuberculosis disease etc.). This has been the sole motivation to establish this Foundation (a non-profit organization). To this end, working on this big goal with constructive and innovative strategies, we hope and look forward to get the chance for providing to the needy a better life and a bright future and a healthy society.
Yours faithfully,
Dr. Suresh Babu Kotini, PhD
Founder & President of Dr. Kotini Foundation
This programme is designed for the financial support to economically backward, exceptionally talented and disciplined students for their education.
This programme is mainly designed for the identification and development of various antibiotics to treat life-threatening infectious diseases.
Mycobacterium tuberculosis (Mtb) is a major human pathogenic bacteria and the causative agent of Tuberculosis (TB) disease. In the most cases, TB is treatable and curable. However, people with TB can die if they do not get proper treatment. Sometimes drug-resistant TB occurs when bacteria becomes resistant to the drugs used to treat TB. This means that the drug can no longer kill the bacteria. TB is highly infectious disease, declared a global health emergency by the World Health Organization (WHO) and is still the second leading killer in the world. According to WHO, in 2017, approx. 11 million (1.1 core) people infected/fell ill with TB disease, and approx. 2 million (20 lakhs) people died from TB disease worldwide and India is the leading the count. This means that, approx. 5,000-6,000 people die each day due to TB disease. Unfortunately, the lack of adherence to prescribed treatment procedure and inefficient healthcare structure have contributed to the development of multidrug-resistant TB (MDR-TB), defined as resistance to at least isoniazid and rifampicin, two front-line drugs used for treatment of TB that requires at least 20 months of treatment of second-line drugs comprised of capreomycin, kanamycin, amikacin and fluoroquinolones; these are more toxic and less efficient, which cure rates in the range of 60-70%. In patients affected by extensively drug-resistant (XDR)-TB, the chances of successful treatment are quite low, underpinning the need for urgent discovery of novel compounds with activity against Mtb strains resistant to second-line drugs and search for new antitubercular drugs is a priority so as to overcome the problem of drug resistance and to finally eradicate TB disease.
The need of new therapies for drug-resistant infections is widely recognized as one of the most serious public health issues facing the world today. ESKAPE (Enterococcus faecium, Staphylococcus aureus, Klebsiella pneumonia, Acinetobacter baumannii, Pseudomonas aeruginosa, and Enterobacter species) pathogens are the leading cause of nosocomial infections (hospital-acquired infections- HAIs) throughout the world. ESKAPE pathogen causes various life-threatening serious infections e.g., Enterococcus faecium causes urinary tract infections, bacteremia, endocarditis, intra-abdominal & pelvic infections, Staphylococcus aureus causes skin infections, pneumonia, meningitis, osteomyelitis, endocarditis, toxic shock syndrome, bacteremia, spesis and wound infections, Klebsiella pneumonia causes pneumonia, blood stream infections, wound infections, urinary tract infections and meningitis, Acinetobacter baumannii causes bacteremia, pneumonia, meningitis, urinary tract infections, wound infections, Pseudomonas aeruginosa causes pneumonia, urinary tract infections, bacteremia, Enterobacter species (Enterobacter cloacae, Enterobacter areogenes etc.) causes respiratory tract infections and urinary tract infections etc. Most of them are multidrug isolates, which is one of the greatest challenges in clinical practice. Multidrug-resistant is amongst the top three threats to global public health and is usually caused by excessive drug usage or prescription, inappropriate use of antimicrobials and substandard pharmaceuticals. Understanding the resistance mechanisms of these bacteria and the development of novel antimicrobial agents (antibiotics) is urgent.
Professional experience/Research/Education:
Board of Director (since 2016) at Suzen Medicare Private Limited, Hyderabad, India
President & Scientific Director (since 2015) at Dr. Kotini Foundation, India
Associate Investigator (Senior Scientist) (2014-2015) at Dept. of Physical Biochemistry, Max Planck Institute for Biophysical Chemistry (Max Planck Society), Gottingen, Germany
Post-doctoral scientist (2011-2014) at Dept. of Physical Biochemistry, Max Planck Institute for Biophysical Chemistry (Max Planck Society), Gottingen, Germany
Ph.D. in Biochemistry & Molecular Biology (2007-2011) at Dept. of Physical Biochemistry, Max Planck Institute for Biophysical Chemistry (Max Planck Society), Gottingen, Germany. Ph.D. thesis advisor: Prof. Dr. Marina V Rodnina (Directors of the Max Planck Society),
Research Fellow (2004-2007) at CSIR-Centre for Cellular and Molecular Biology (CCMB), Hyderabad, India
MSc. in Microbiology (2002-2004) from Acharya Nagarjuna University, Guntur, India
Honors/awards/research grants received:
In 2007, Selected for International PhD programme of GGNB (Gottingen Graduate School for Neurosciences, Biophysics, and Molecular Biosciences) to pursue Ph.D. at Max Planck Institute for Biophysical Chemistry, Gottingen, Germany
Max Planck Society stipend for doctoral research (2007-2011)
Dr.rer. nat. (Doctor of Natural Science) awarded (2011) with “Magna Cum Laude” (“with great honor”) by the University of Gottingen, Gottingen, Germany
Research grants received (2011-2015) from German Research Foundation(DFG) & Max Planck Society to carry out research at Max Planck Institute for Biophysical Chemistry, Gottingen, Germany
Memberships (National and International):
The World Association for Infectious Diseases and Immunological Disorders (WAidid), Milano, Italy,
International Society for Infectious Diseases (ISID),Massachusetts, USA,
British Infection Association (BIA) Edinburgh, UK,
World Association of Young Scientists (WAYS),
Dr. Kotini Foundation joined the “Stop TB Partnership”. Stop TB partnership administered by United Nations Office for Project Services (UNOPS), Geneva, Switzerland,
International Union Against Tuberculosis and Lung Disease, Paris, France,
British Society for Antimicrobial Chemotherapy, Birmingham, UK,
Registered for – The Global Health Network – Antimicrobial Resistance (AMR), University of Oxford, UK,
.jpg)
Project summary: Identification and development of novel or new class of antibiotics to against ESKAPE pathogens